Early consideration of biologics such as anti-TNF-α has been suggested for the treatment of a newly reported clinical entity called Pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2 (PIMS-TS) or Pediatric Multisystem Inflammatory Syndrome (MIS-C) [27, 28]. The gene discussed is TNF; the disease is COVID-19–associated multisystem inflammatory syndrome in children.